Bromfenac Sodium 0.1%, Fluorometholone 0.1% and Dexamethasone 0.1% for Control of Ocular Inflammation and Prevention of Cystoid Macular Edema after Phacoemulsification

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002600

Enrollment

Unknown

Registered

2012-10-16

Start date

2010-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Inflammation and Cystoid Macular Edema after Phacoemulsification

Interventions

OBS1:The OBS1 group received ophthalmic bromfenac sodium

OBS2:The OBS2 group received ophthalmic bromfenac sodium

OFM:The OFM group received ophthalmic fluorometholone

ODM:The OFM group received 0.1% dexamethasone eye drop

Eligibility

Sex/Gender

All

Age

46 Years to 92 Years

Inclusion criteria

Inclusion criteria: age-related cataract patients undergoing phacoemulsification with posterior chamber intraocular lens implantation

Exclusion criteria

Exclusion criteria: (1) patients who were suffering from any ocular diseases that might affect treatment responses or evaluations, such as corneal disease, glaucoma, uveitis, retinal detachment, optic neuropathy or amblyopia; (2) patients who were suffering with any systemic diseases that might affect treatment responses or evaluations, such as diabetes mellitus; (3) potentially pregnant women; and (4) patients who had received systemic or topical anti-inflammatory therapy within 1 month prior to surgery.

Design outcomes

Primary

Measure	Time frame
photon count value;Retinal foveal thickness;intraocular pressur;	—

Secondary

Measure	Time frame
best-correct visual acuity;endothelial cell density;	—

Countries

China

Contacts

Public ContactYao Ke

xlren@zju.edu.cn+86 0571-87783897

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026